McClarren Financial Advisors Inc. Increases Stock Position in Bristol-Myers Squibb (NYSE:BMY)

McClarren Financial Advisors Inc. raised its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 532.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,879 shares of the biopharmaceutical company’s stock after acquiring an additional 1,582 shares during the quarter. McClarren Financial Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $96,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in BMY. OFI Invest Asset Management purchased a new position in Bristol-Myers Squibb in the third quarter valued at about $25,000. Milestone Investment Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at about $27,000. Blue Bell Private Wealth Management LLC grew its position in shares of Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 200 shares during the last quarter. Legacy Financial Group LLC bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $39,000. Finally, VisionPoint Advisory Group LLC lifted its position in Bristol-Myers Squibb by 300.5% during the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 553 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Price Performance

BMY stock traded down $4.18 during mid-day trading on Thursday, reaching $44.68. 45,047,382 shares of the company’s stock were exchanged, compared to its average volume of 15,901,512. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. Bristol-Myers Squibb has a 12-month low of $44.37 and a 12-month high of $69.74. The stock’s 50 day moving average is $51.13 and its 200 day moving average is $51.26. The company has a market cap of $90.56 billion, a price-to-earnings ratio of 11.58, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business’s revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.05 EPS. On average, research analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 5.37%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on BMY shares. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. Finally, Bank of America cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $68.00 to $60.00 in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.